KOBAYASHI PHARMACEUTICAL Aktie

 

Kobayashi Pharmaceutical Co., the Japanese health products company that was at the center of a supplement contamination scandal involving suspected deaths, is said to be considering a potential buyout offer of more than ¥500 billion ($3.2 billion) by private equity investors....

Osaka, March 27 (Jiji Press)--Kobayashi Pharmaceutical Co. rejected Friday management reform proposals by the top shareholder in the Osaka-based producer of health problem-causing supplements containing "beni koji" red fermented rice. At the day's general shareholders meeting in the western Japan city, Hong Kong-based investment fund Oasis Management Co., which holds a 13.7 pct stake in Koba......

* Although Oasis generally supports the separation of business execution and oversight, Oasis is calling on shareholders to vote AGAINST Kobayashi Pharma transitioning to a Company with an Audit and Supervisory Committee, as Oasis believes it may further entrench the founding family's control over the Company * Oasis continues to urge all shareholders to vote AGAINST the election of Akihiro Kobayashi and Yoshiro Katae as Directors * Oasis withdrew its proposal to elect Mr. Kawaguchi, as the Company's proposed amendment to its Articles of Incorporation has effectively rendered Oasis's proposal meaningless *Oasis continues to urge all shareholders to vote FOR its other shareholder proposals More information available at www.KobayashiCorpGov.comHONG KONG--(BUSINESS WIRE)--Oasis Management Company Ltd. (“Oasis”) is the manager to funds that beneficially own over 13.1% of Japanese pharmaceuticals and food products manufacturer Kobayashi Pharmaceutical Co., Ltd. (4967 JT) (“Kobayashi Pharma” or the ?...

Tokyo, March 5 (Jiji Press)--A Japanese research team has uncovered a part of the mechanism by which a substance found in Kobayashi Pharmaceutical Co.'s supplements containing "beni koji," or red fermented rice, triggered kidney damage, it was learned Thursday. Although it had been known that puberulic acid derived from blue mold was behind the high-profile health scare involving the supple......

TOKYO (dpa-AFX) - Kobayashi Pharmaceutical Co., Ltd. (KBYPF) announced earnings for full year that Dropped, from last yearThe company's earnings came in at JPY3.656 billion, or JPY49.19 per share.......

TOKYO (dpa-AFX) - Kobayashi Pharmaceutical Co. Ltd.(KBYPF, 4967.T) registered a decline in net profit for the third quarter. However, the company recorded an increase in sales, driven by the full-......

Osaka, Aug. 23 (Jiji Press)--Kobayashi Pharmaceutical Co. said Friday that it has expanded its factory in Georgia to double the production capacity of disposable hand warmers to meet growing demand in the United States. The 8-billion-yen expansion was completed on Aug. 12, the Japanese company said. The expanded facility is expected to go into operation by the end of fiscal 2025. The product......